Research progress of surface modified albumin nanoparticles in tumor targeting therapy

Abstract

Abstract:

At present, most drugs for clinical cancer therapy are non-selective, with the inhibition of tumor cell proliferation, they also have significant side effects on normal tissues, thereby improving the tumor-selective capacity, reducing their gathering in non-targeted areas are the keys to enhance the effectiveness of anti-cancer drugs. As drug carriers, albumin nanoparticles exhibit various outstanding biological properties, and now have been used in targeted delivery systems. The paper reviews the albumin's tumor aggregation features, the latest researches in the targeted therapy of tumor and clinical applications when they are modified with RGD peptides, monoclonal antibodies, folic acid, hyaluronic acid, transferrin and other targeted material，in order to provide advices for developing safe and effective tumor targeting drugs.

Key words: albumin nanoparticles, targeted modification, tumor therapy, applications

CLC Number:

XU Lihua, XU Xiaoyang, XU Junjun, YU Wenying. Research progress of surface modified albumin nanoparticles in tumor targeting therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 948-954.

References

［1］Heinrich AK, Lucas H, Schindler L, et al. Improved tumor specific drug accumulation by polymer therapeutics with pH-sensitive drug release overcomes chemotherapy resistance［J］. Mol Cancer Ther, 2016, 15(5): 998-1007.
［2］Navai SA, Ahmed N. Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells ［J］. Biochem Soc Trans, 2016, 44(2): 391-396.
［3］Ruttala HB, Ko YT. Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy ［J］. Pharm Res, 2014, 32(3):1002-1016.
［4］Loureiro A, Azoia NG, Gomes AC, et al. Albumin-based nanodevices as drug carriers ［J］. Curr Pharm Des, 2016, 22(10): 1371-1390.
［5］Lohcharoenkal W, Wang L, Chen YC, et al. Protein nanoparticles as drug delivery carriers for cancer therapy ［J］. Biomed Res Int, 2014, 2014(1):180549.
［6］Battogtokh G, Kang JH, Ko YT. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug ［J］. Eur J Pharm Biopharm, 2015, 96: 96-105.
［7］Jacobs SA, Gibbs AC, Conk M, et al. Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics［J］. Protein Eng Des Sel, 2015, 28(10):385-395.
［8］Kinoshita R, Ishima Y, Ikeda M, et al. S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes ［J］. J Controlled Release, 2015, 217:1-9.
［9］Reddic RL, Zhang SH, Maeda N, et al. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression ［J］. Arterioscler Thromb, 1994, 14(1):141-147.
［10］Mocan L, Matea C, Tabaran FA, et al. Photothermal treatment of liver cancer with albumin-conjugated gold nanoparticles initiates Golgi Apparatus-ER dysfunction and caspase-3 apoptotic pathway activation by selective targeting of Gp60 receptor ［J］. Int J Nanomedicine, 2015, 2015(10): 5435-5445.
［11］Botos E, Klumperman J, Oorschot V, et al. Caveolin-1 is transported to multi-vesicular bodies after albumin-induced endocytosis of caveolae in HepG2 cells ［J］. J Cell Med, 2008, 12(5a): 1632-1639.
［12］Hoang B, Ernsting MJ, Roy A, et al. Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism ［J］. Biomaterials, 2015, 59: 66-76.
［13］Yin T, Cai H, Liu J, et al. Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel ［J］. Eur J Pharm Sci, 2015, 83: 79-87.
［14］柳莹, 武鑫, 刘皋林,等. 适配体修饰的纳米粒在肿瘤诊断与治疗中的应用［J］. 中国临床药理学与治疗学, 2016, 21(3): 341-346.
［15］Dingjan T, Spendlove I, Durrant LG, et al. Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies ［J］. Mol Immunol, 2015, 67(2 Pt A): 75-88.
［16］Guo Z, He B, Jin H, et al. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering ［J］. Biomaterials, 2014, 35(23): 6106-6017.
［17］Fiorini C, Cordani M, Padroni C, et al. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine ［J］. Biochim Biophys Acta, 2015, 1853(1): 89-100.
［18］Ji S, Xu J, Zhang B, et al . RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy ［J］. Cancer Biol Ther, 2012, 13(4): 206-215.
［19］Ming X, Carver K, Wu L. Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides ［J］. Biomaterials, 2013, 34(32): 7939-7949.
［20］Bhunia SK, Maity AR, Nandi S, et al. Imaging cancer cells expressing the folate receptor with carbon dots produced from folic acid ［J］. Chembiochem, 2016, 17(7): 614-619.
［21］Shen Z, Li Y, Kohama K, et al. Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres ［J］. Pharmacol Res, 2011, 63(1): 51-58.
［22］Qi L, Guo Y, Luan J, et al. Folate-modified bexarotene-loaded bovine serum albumin nanoparticles as a promising tumor-targeting delivery system ［J］. J Mater Chem B, 2014, 2(47): 8361-8371.
［23］Feng L, Wang W, Yao HP, et al. Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases ［J］. Methods Mol Biol, 2015, 1233: 151-159.
［24］Fadaeian G, Shojaosadati SA, Kouchakzadeh H, et al. Targeted delivery of 5-fluorouracil with monoclonal antibody modified bovine serum albumin nanoparticles ［J］. Iran J Pharm Res, 2015, 14(2): 395-405.
［25］Hapuarachchige S, Zhu W, Kato Y, et al. Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics ［J］. Biomaterials, 2014, 35(7):2346-2354.
［26］Li W, Yi X, Liu X, et al. Hyaluronic acid ion pairing nanoparticles for targeted tumor therapy ［J］. J Control Release, 2016, 225: 170-182.
［27］Zhong Y, Zhang J, Cheng R, et al. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts ［J］. J Control Release, 2015, 205:144-154.
［28］Pulakkat S, Balaji SA, Rangarajan A, et al. Surface engineered protein nanoparticles with hyaluronic acid based multilayers for targeted delivery of anticancer agents ［J］. ACS Appl Mater Interfaces, 2016, 8(36): 23437-23449.
［29］方奕巍, 尹宗宁. 透明质酸修饰的白蛋白纳米粒的制备及抗肿瘤作用的初步评价［J］. 四川大学学报医学版, 2011, 42(4): 480-484.
［30］Kolhatkar R, Lote A, Khambati H. Active tumor targeting of nanomaterials using folic acid, transferrin and integrin receptors ［J］. Curr Drug Discov Technol, 2011, 8(3): 197-206.
［31］Wang X, Huang X, Yang Z, et al. Targeted delivery of tumor suppressor microrna-1 by transferrin- conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells ［J］. Curr Pharm Biotechnol, 2014, 15(9): 839-846.
［32］Bae S, Ma K, Kim TH, et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types ［J］. Biomaterials, 2012, 33(5): 1536-1546.
［33］Yan G, Wang J, Hu L, et al. Stepwise targeted drug delivery to liver cancer cells for enhanced therapeutic efficacy by galactose-grafted, ultra-pH-sensitive micelles ［J］. Acta Biomater, 2017, pii: S1742-7061(17)30031-4.
［34］Mehdizadeh M, Rouhani H, Sepehri N, et al. Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy ［J］. Artif Cells Nanomed Biotechnol, 2016, 45(3): 1-10.
［35］Taheri A, Dinarvand R, Nouri FS, et al. Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy ［J］. Int J Nanomedicine, 2011, 6(6): 1863-1874.
［36］Kesharwani P, Jain A, Jain A, et al. Cationic bovine serum albumin (CBA) conjugated poly lactic-co-glycolic acid (PLGA) nanoparticles for extended delivery of methotrexate into brain tumor ［J］. Rsc Adv, 2016, 6(92): 89040-89050.
［37］Byeon HJ, Le QT, Lee S, et al. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors ［J］. J Cont Rel, 2016, 225: 301-313.
［38］郝和群. 具有肿瘤靶向功能的阿霉素/白蛋白-葡聚糖纳米粒子［D］. 复旦大学, 2013.
［39］Qi WW, Yu HY, Guo J, et al. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy ［J］. Mol Pharm, 2015, 12(3): 675-683.
［40］Li C, Zhang D, Guo H, et al. Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin ［J］. Int J Pharm, 2013, 448(1): 79-86.
［41］Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer ［J］. Ann Oncol, 2006, 17(8): 1263-1268.
［42］姬时宇, 胡毅. 白蛋白结合型紫杉醇治疗晚期原发性肝癌的效果观察［J］. 临床肝胆病杂志, 2016, 32(10): 1911-1915.
［43］Gonzalezangulo AM, Mericbernstam F, Chawla S, et al. Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial ［J］. Clin Cancer Res, 2013, 19(19): 5474-5484.
［44］Ueno NT, Mamounas EP. Neoadjuvant nab-paclitaxel in the treatment of breast cancer ［J］. Breast Cancer Res Treat, 2016, 156(3): 427-440.
［45］Blair HA, Deeks ED. Albumin-bound paclitaxel: a review in non-small cell lung cancer ［J］. Drugs, 2015, 75(17): 2017-2024.
［46］John A. ABI-008 trial in patients with hormone-refractory prostate cancer. available at: https://clinicaltrials.gov/ct2/show/NCT00477529?term=ABI-008&rank=1.html ［EB/OL］.
［47］Nuhad KI. ABI-008 trial in patients with metastatic breast cancer. available at: https://clinicaltrials.gov/ct2/show/NCT00531271 term=ABI-008&rank=2.html ［EB/OL］.
［48］Ana M, Sant P. ABI-009 trial in patients with advanced non-hematologic malignancies. available at: https://clinicaltrials.gov/ct2/show/NCT00635284?term=ABI-009&rank=1.html ［EB/OL］.
［49］James MK. Phase 1/2 study of ABI-009 in nonmuscle invasive bladder cancer. available at: https://clinicaltrials.gov/ct2/show/NCT02009332?term=ABI-009&rank=3.html ［EB/OL］.
［50］Patricia ML, John S. A phase 1 trial of ABI-011 in patients with advanced solid tumors or lymphomas. available at: https://clinicaltrials.gov/ct2/show/NCT01163071?term=ABI-011& rank=2.html ［EB/OL］.

[1]	SHAO Mingkun, LIU Rong, SUN Pin, GUAN Shui, LIAO Bingcan, LI Sha, CONG Tao, LIANG Kai, MA Hui, SUN Changkai. Human body networks mechanisms of melatonin and its clinical applications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1031-1040.
[2]	ZHAO Xiaobin, YU Chenhuan, XIA Aixiao, YU Wenying, YU Bing. Recent advances of nanocarriers targeting tumor-associated macrophages in tumor therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 830-835.
[3]	WANG Zi-hao, WANG Xue-feng, JIANG Han, WANG Jina-dong, SHI Wei-bin. Domestic clinical research progress of photosensitive anticancer drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(1): 107-111.